BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 37182132)

  • 1. The dual role of p63 in cancer.
    Xu Y; Yang X; Xiong Q; Han J; Zhu Q
    Front Oncol; 2023; 13():1116061. PubMed ID: 37182132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One, two, three--p53, p63, p73 and chemosensitivity.
    Müller M; Schleithoff ES; Stremmel W; Melino G; Krammer PH; Schilling T
    Drug Resist Updat; 2006 Dec; 9(6):288-306. PubMed ID: 17287142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 family members and human cancers.
    Bénard J; Douc-Rasy S; Ahomadegbe JC
    Hum Mutat; 2003 Mar; 21(3):182-91. PubMed ID: 12619104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ΔNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis.
    Park S; Lee S; Kim J; Kim G; Park KH; Kim TU; Chung D; Lee H
    PLoS One; 2019; 14(4):e0214867. PubMed ID: 30973901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p63 (TA and deltaN isoforms) in human primary well differentiated buccal carcinomas.
    Chen YK; Hsue SS; Lin LM
    Int J Oral Maxillofac Surg; 2004 Jul; 33(5):493-7. PubMed ID: 15183414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
    Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
    J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p63-related signaling at a glance.
    Fisher ML; Balinth S; Mills AA
    J Cell Sci; 2020 Sep; 133(17):. PubMed ID: 32917730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.
    Muttray AF; Cox RL; Reinisch CL; Baldwin SA
    Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry.
    Nekulova M; Holcakova J; Nenutil R; Stratmann R; Bouchalova P; Müller P; Mouková L; Coates PJ; Vojtesek B
    Virchows Arch; 2013 Sep; 463(3):415-25. PubMed ID: 23887585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of p63 and p73 in human cancers.
    Inoue K; Fry EA
    Subcell Biochem; 2014; 85():17-40. PubMed ID: 25201187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p63 and p73: roles in development and tumor formation.
    Moll UM; Slade N
    Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.
    Coates PJ; Nenutil R; Holcakova J; Nekulova M; Podhorec J; Svoboda M; Vojtesek B
    Virchows Arch; 2018 Mar; 472(3):351-359. PubMed ID: 29484502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells.
    Petitjean A; Cavard C; Shi H; Tribollet V; Hainaut P; Caron de Fromentel C
    Oncogene; 2005 Jan; 24(3):512-9. PubMed ID: 15543231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.
    Venkatanarayan A; Raulji P; Norton W; Flores ER
    Cell Cycle; 2016; 15(2):164-71. PubMed ID: 26652033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression and ratio disruption of ΔNp63 and TAp63 isoform equilibrium in endometrial adenocarcinoma: correlation with obesity, menopause, and grade I/II tumors.
    Vakonaki E; Soulitzis N; Sifakis S; Papadogianni D; Koutroulakis D; Spandidos DA
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1271-8. PubMed ID: 22441934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73.
    Petitjean A; Ruptier C; Tribollet V; Hautefeuille A; Chardon F; Cavard C; Puisieux A; Hainaut P; Caron de Fromentel C
    Carcinogenesis; 2008 Feb; 29(2):273-81. PubMed ID: 18048390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells.
    Vayssade M; Haddada H; Faridoni-Laurens L; Tourpin S; Valent A; Bénard J; Ahomadegbe JC
    Int J Cancer; 2005 Oct; 116(6):860-9. PubMed ID: 15849742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide p63-Target Gene Analyses Reveal TAp63/NRF2-Dependent Oxidative Stress Responses.
    Napoli M; Deshpande AA; Chakravarti D; Rajapakshe K; Gunaratne PH; Coarfa C; Flores ER
    Cancer Res Commun; 2024 Feb; 4(2):264-278. PubMed ID: 38165157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The foggy world(s) of p63 isoform regulation in normal cells and cancer.
    Pokorná Z; Vysloužil J; Hrabal V; Vojtěšek B; Coates PJ
    J Pathol; 2021 Jul; 254(4):454-473. PubMed ID: 33638205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of p63 isoforms in normal tissues and neoplastic cells.
    Nylander K; Vojtesek B; Nenutil R; Lindgren B; Roos G; Zhanxiang W; Sjöström B; Dahlqvist A; Coates PJ
    J Pathol; 2002 Dec; 198(4):417-27. PubMed ID: 12434410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.